01—Abstract
Summary
Summary of the 10-Q filed August 5, 2026. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. reported second-quarter 2026 total revenue of $1,004.1 milliona, down $28.1 million, or 2.7%, from $1,032.1 million a year earlier.
Revenue for the six months ended June 27, 2026 was $1,999.9 millionb, down 0.8% from $2,016.3 million. The decline reflected the sale of the CDMO business and the European Discovery Services divestiture, along with lower cell supply revenue. Operating income rose to $119.9 million, or 11.9% of revenue, from $100.1 million, or 9.7%, mainly because of a gain on the Wilmington, Massachusetts asset sale, lower accelerated amortization, and lower 2025 third-party legal costs.
Net loss attributable to common shareholders was $1.5 millionc for the quarter, compared with net income of $52.3 million in the prior-year quarter. The result was driven by a $63.7 million loss on the CDMO and Cell Solutions divestiture. For the six months, the company reported a net loss attributable to common shareholders of $16.3 million, including a $181.7 million divestiture loss.
Cash flow from operations was $220.8 milliond for the six months, compared with $376.3 million a year earlier. The company attributed the decline to higher variable compensation payments and acquisition, integration and divestiture-related payments. Investing activities included $467.3 million for acquisitions, primarily the Cambodian NHP supplier with a preliminary purchase price of $507.3 million, and PathoQuest, at $67.6 million.
Total long-term debt, net and finance leases rose to $2.62 billion from $2.14 billion, with the revolving facility balance increasing to $1.12 billion from $616.5 million. The company repurchased $300.0 million of stock during the six months and had $700.0 million remaining under its repurchase authorization at June 27, 2026. Management stated that cumulative annualized cost savings of approximately $300 million are expected by the end of 2026, and that DSA backlog increased slightly to $2.0 billion from $1.9 billion.
The filing also discloses a putative securities class action and two derivative lawsuits, which management believes are without merit. The company cannot reasonably estimate the potential exposure from these matters.
02—Key points
Key Highlights
- Q2 2026 total revenue was $1,004.1 million, down $28.1 million, or 2.7%, versus $1,032.1 million in Q2 2025, primarily due to the CDMO and European Discovery divestitures.
- Q2 2026 operating income was $119.9 million (11.9% of revenue) versus $100.1 million (9.7%) a year earlier, aided by a $38.5 million Wilmington site sale gain recognized in Q1 2026.
- Net loss attributable to common shareholders was $1.5 million in Q2 2026, versus net income of $52.3 million in Q2 2025, due principally to a $63.7 million CDMO and Cell Solutions divestiture loss; diluted EPS was $(0.03).
- Six-month operating cash flow declined to $220.8 million from $376.3 million, reflecting higher annual bonus payments and acquisition and divestiture-related payments.
- Acquisitions included the Cambodian NHP supplier (preliminary purchase price $507.3 million, with $105.0 million of deferred consideration still unpaid) and PathoQuest ($67.6 million).
- Long-term debt, net and finance leases increased to $2,620.0 million from $2,136.4 million, with the revolving facility at $1,120.3 million; cash and cash equivalents were $192.0 million.
- The company repurchased $300.0 million of stock in the first half of 2026 and had $700.0 million remaining under its $1.0 billion repurchase program; management expects about $300 million in cumulative annualized cost savings by end of 2026.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2026filed August 5, 2026Financial Statements
Q2 FY2026 against Q2 FY2025
| Line item | Q2 FY2026Q2 FY2025 | Change |
|---|---|---|
| Revenue | $1.00B$1.03B | −2.7% |
| SG&A Expenses | $228.90M$191.55M | +19.5% |
| Operating Income | $119.89M$100.13M | +19.7% |
| Net Income | -$1.48M$52.33M | −102.8% |
| EPS (Basic) | $-0.03$1.06 | −102.8% |
| EPS (Diluted) | $-0.03$1.06 | −102.8% |
| Shares Outstanding (Basic) | 48.02M49.15M | −2.3% |
| Shares Outstanding (Diluted) | 48.02M49.32M | −2.6% |
05—Questions
Frequently Asked Questions
Why did the company report a net loss for the quarter despite higher operating income?
Operating income rose to $119.9 million from $100.1 million, but other expense, net was $37.4 million in Q2 2026, mainly due to a $63.7 million loss on the CDMO and Cell Solutions divestiture. The effective tax rate was 101.4%, with the tax provision at $53.9 million, which together produced a net loss of $0.8 million before noncontrolling interests.
What is driving the decline in revenue?
The filing attributes the revenue decrease primarily to lower Manufacturing revenue from the sale of the CDMO business and lower DSA revenue from the European Discovery Divestiture, with a smaller contribution from lower RMS revenue due to decreased cell supply revenue.
How is the company funding its acquisitions and share repurchases?
The company funded the Cambodian NHP supplier and PathoQuest acquisitions through a combination of cash on hand and borrowings under its Credit Facility. Net proceeds from long-term debt and the revolving facility were $1,265.3 million in proceeds against $745.9 million of payments for the six months, and the company purchased $323.9 million of treasury stock in cash flow terms.
What are the main legal risks disclosed?
The filing describes a putative securities class action filed in May 2023 concerning NHP importation disclosures, which was partially revived on appeal in August 2025, and two derivative lawsuits. The company believes these claims are without merit and plans to defend them vigorously, but states it cannot reasonably estimate the maximum potential exposure or range of possible loss.
06—Continue